Angiogénesis
Los inhibidores de la angiogénesis son compuestos que interfieren con la formación de nuevos vasos sanguíneos, un proceso crucial en el crecimiento y la metástasis del cáncer. Al inhibir la angiogénesis, estos compuestos pueden restringir el suministro de sangre a los tumores, ralentizando o deteniendo su crecimiento. Los inhibidores de la angiogénesis son esenciales en la investigación del cáncer y en el desarrollo terapéutico, proporcionando información sobre los mecanismos de progresión tumoral y ofreciendo posibles tratamientos para el cáncer y otras enfermedades relacionadas con la angiogénesis. En CymitQuimica, ofrecemos una amplia gama de inhibidores de la angiogénesis de alta calidad para apoyar su investigación en oncología y biología vascular.
Subcategorías de "Angiogénesis"
- BTK(166 productos)
- Bcr-Abl(117 productos)
- EGFR(550 productos)
- FAK(72 productos)
- FLT(88 productos)
- Receptor del factor de crecimiento de fibroblastos (FGFR)(176 productos)
- JAK(243 productos)
- PDGFR(127 productos)
- RAAS(86 productos)
- Src(82 productos)
- Syk(37 productos)
- Trombina(51 productos)
- VDA(2 productos)
- VEGFR(236 productos)
Mostrar 6 subcategorías más
Se han encontrado 2267 productos de "Angiogénesis"
Ordenar por
Pureza (%)
0
100
|
0
|
50
|
90
|
95
|
100
FGFR-IN-4
CAS:FGFR-IN-4 is a potent inhibitor of FGFR. FGFR-IN-4 has potential for cancer disease studies.Fórmula:C24H21N7O2Forma y color:SolidPeso molecular:439.47JAK-IN-1
CAS:JAK-IN-1 shows improved selectivity for JAK3 over JAK1. JAK-IN-1 is a JAK1/2/3 inhibitor with IC50s of 0.26, 0.8 and 3.2 nM, respectively.Fórmula:C20H24N6O2Pureza:98%Forma y color:SolidPeso molecular:380.44HPK1-IN-2 dihydrochloride
CAS:HPK1-IN-2 dihydrochloride, a potent and orally active inhibitor of hematopoietic progenitor kinase-1 (HPK1) with an IC 50 of less than 0.05 µM, demonstrates significant antitumor activity. It additionally exhibits inhibition of Lck kinase activity, with an IC 50 ranging from 0.05 to less than 0.5 µM, and Flt3 kinase activity, with an IC 50 of less than 0.05 µM [1].Fórmula:C19H22Cl2N6OSForma y color:SolidPeso molecular:453.39TIE-2/VEGFR-2 kinase-IN-3
CAS:TIE-2/VEGFR-2 kinase-IN-3, a benzimidazole derivative, serves as a potent inhibitor of the tyrosine kinase receptors TIE-2 and VEGFR-2, exhibiting IC50 valuesFórmula:C23H17F4N5O3SForma y color:SolidPeso molecular:519.47VEGFR-2-IN-37
CAS:VEGFR-2-IN-37 (compound 12), a VEGFR-2 inhibitor, exhibits an inhibition rate of approximately 56.9 μM at a concentration of 200 μM.Fórmula:C18H16N2O2SPureza:98%Forma y color:SolidPeso molecular:324.4FGFR4-IN-16
CAS:FGFR4-IN-16 (CY-15-2) is a covalent inhibitor targeting FGFR-4, utilized in cancer research [1].Fórmula:C35H30Cl2N6O5Pureza:98%Forma y color:SolidPeso molecular:685.56Cinsebrutinib
CAS:Cinsebrutinib, a Bruton's tyrosine kinase inhibitor, holds potential for research in cancer treatment.Fórmula:C22H26FN3O2Pureza:98%Forma y color:SolidPeso molecular:383.46FLT3-IN-14
CAS:FLT3-IN-14: FLT3 inhibitor; FLT3-WT IC50=5.6nM, FLT3-ITD IC50=1.4nM; blocks Y591 phosphorylation; G1 arrest; pro-apoptotic.Fórmula:C25H24N6O2SForma y color:SolidPeso molecular:472.56Brolucizumab
CAS:Brolucizumab (anti-VEGF-A scFv) potently blocks VEGF-A to reduce neovascularization in wet AMD, with picomolar binding affinity.Pureza:95%Forma y color:LiquidPeso molecular:~150 kDaSulfatinib
CAS:Sulfatinib (KDR-IN-1) (HMPL-012) is a potent and highly selective tyrosine kinase inhibitor against VEGFR1/2/3, FGFR1 and CSF1R with IC 50 s ranging from 1 toFórmula:C24H28N6O3SPureza:99.21% - >99.99%Forma y color:SolidPeso molecular:480.58KB SRC 4
CAS:KB SRC 4 is a selective and potent c-Src inhibitor with antitumour activity that inhibits the growth of cancer cells.CAS 번호13460-73-83-4Fórmula:C32H23ClN8Pureza:98.83% - 99.34%Forma y color:SolidPeso molecular:555.03Pivanex
CAS:Pivanex, an oral HDAC inhibitor, targets metastasis, angiogenesis, reduces Bcr-Abl protein, and promotes apoptosis.Fórmula:C10H18O4Pureza:≥98%Forma y color:SolidPeso molecular:202.25AKB-6899
CAS:AKB-6899 is an inhibitor of prolyl hydroxylase domain 3 (PHD3) and increases the soluble form of the VEGF receptor (sVEGFR-1) production from GM-CSF-treatedFórmula:C14H11FN2O4Pureza:97.87%Forma y color:SolidPeso molecular:290.25FC 11
CAS:FC 11 is a reversible FAK PROTAC Degrader with DC50 of 40-370 pM and degrades pFAKtyr397 in TM3 cells within 3 hours at 100 nM.Fórmula:C41H42F3N13O9SForma y color:SolidPeso molecular:949.91HER2-IN-5
CAS:HER2-IN-5 is an effective inhibitor of orally active HER-2.Fórmula:C27H33N7O3Forma y color:SolidPeso molecular:503.6Simotinib
CAS:Simotinib (AL-6802) is an EGFR tyrosine kinase inhibitor (IC50 : 19.9 nM) with antitumour activity for the study of non-small cell lung cancer.Fórmula:C25H26ClFN4O4Pureza:99.7%Forma y color:SolidPeso molecular:500.95Nazartinib S-enantiomer
CAS:Nazartinib is an EGFR inhibitor. Nazartinib S-enantiomer is the less active S-enantiomer of Nazartinib.Fórmula:C26H31ClN6O2Pureza:98%Forma y color:SolidPeso molecular:495.02JAK-IN-25
CAS:JAK-IN-25 (compound 19), a potent JAK inhibitor, exhibits IC50 values of 6 nM for TYK2, 21 nM for JAK1, 8 nM for JAK2, and 1051 nM for JAK3.Fórmula:C19H17N5O4Pureza:98%Forma y color:SolidPeso molecular:379.37VEGFR2-IN-3
CAS:VEGFR2-IN-3 (compound 385) is a potent inhibitor of VEGFR2 [1].Fórmula:C26H28ClN5O4Pureza:98%Forma y color:SolidPeso molecular:509.98EGFR-IN-71
CAS:EGFR-IN-71 is a potent inhibitor of epidermal growth factor receptor (EGFR) (IC50= 3.7 μM). EGFR-IN-71 has research value in chordoma.
Fórmula:C16H9ClIN3Forma y color:SolidPeso molecular:405.62
